Introgen Therapeutics, Inc. Announces Second Quarter 2005 Earnings Conference Call

    AUSTIN, Texas, Aug. 5 /PRNewswire-FirstCall/ -- Introgen Therapeutics,
 Inc. (Nasdaq:   INGN), a leading developer of biopharmaceutical products for the
 treatment of cancer and other diseases, will hold its quarterly conference
 call to discuss second quarter results on Tuesday, August 9, 2005, at
 4:30 p.m. Eastern Time (3:30 p.m. Central Time).
     This call is being webcast by Thomson/CCBN and can be accessed at
 Introgen's Web site at http://www.introgen.com .
     The webcast is also being distributed through the Thomson StreetEvents
 Network to both institutional and individual investors.  Individual investors
 can listen to the call at http://www.fulldisclosure.com , Thomson/CCBN's
 individual investor portal, powered by StreetEvents.  Institutional investors
 can access the call via Thomson's password-protected event management site,
 StreetEvents (http://www.streetevents.com ).
 
     About Introgen Therapeutics, Inc.
     Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the
 discovery, development and commercialization of targeted molecular therapies
 for the treatment of cancer and other diseases.  Introgen is developing
 molecular therapeutics, immunotherapies, vaccines and nano-particle tumor
 suppressor therapies to treat a wide range of cancers using non-integrating
 tumor suppressors, cytokines and genes.  Introgen maintains integrated
 research, development, manufacturing, clinical and regulatory departments and
 operates multiple manufacturing facilities including a commercial scale cGMP
 manufacturing facility.
 
      Contact Information:
      Channing Burke
      (512) 708-9310 Ext. 322
      c.burke@introgen.com
 
 

SOURCE Introgen Therapeutics, Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.